158 related articles for article (PubMed ID: 28279416)
1. Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based Therapy.
Kenigsberg B; Jain V; Barac A
Heart Fail Clin; 2017 Apr; 13(2):297-309. PubMed ID: 28279416
[TBL] [Abstract][Full Text] [Related]
2. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
3. Management of Heart Failure in Cancer Patients and Cancer Survivors.
Finet JE
Heart Fail Clin; 2017 Apr; 13(2):253-288. PubMed ID: 28279414
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics.
Hervent AS; De Keulenaer GW
Int J Mol Sci; 2012 Sep; 13(10):12268-86. PubMed ID: 23202898
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
6. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
7. Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.
Huang S; Peter Rodemann H; Harari PM
Recent Results Cancer Res; 2016; 198():45-87. PubMed ID: 27318681
[TBL] [Abstract][Full Text] [Related]
8. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.
De Keulenaer GW; Doggen K; Lemmens K
Circ Res; 2010 Jan; 106(1):35-46. PubMed ID: 20056944
[TBL] [Abstract][Full Text] [Related]
9. Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
Albini A; Cesana E; Donatelli F; Cammarota R; Bucci EO; Baravelli M; AnzĂ C; Noonan DM
Future Cardiol; 2011 Sep; 7(5):693-704. PubMed ID: 21929348
[TBL] [Abstract][Full Text] [Related]
10. Targeting HER1/EGFR: a molecular approach to cancer therapy.
Arteaga C
Semin Oncol; 2003 Jun; 30(3 Suppl 7):3-14. PubMed ID: 12840796
[TBL] [Abstract][Full Text] [Related]
11. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
[TBL] [Abstract][Full Text] [Related]
12. Heart Failure With Targeted Cancer Therapies: Mechanisms and Cardioprotection.
Hahn VS; Zhang KW; Sun L; Narayan V; Lenihan DJ; Ky B
Circ Res; 2021 May; 128(10):1576-1593. PubMed ID: 33983833
[TBL] [Abstract][Full Text] [Related]
13. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
[TBL] [Abstract][Full Text] [Related]
14. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
15. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
16. EGFR signaling and drug discovery.
Lurje G; Lenz HJ
Oncology; 2009; 77(6):400-10. PubMed ID: 20130423
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic growth factor receptors: implications for signal transduction therapy.
Mosesson Y; Yarden Y
Semin Cancer Biol; 2004 Aug; 14(4):262-70. PubMed ID: 15219619
[TBL] [Abstract][Full Text] [Related]
18. The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors.
Engelman JA; Cantley LC
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4372s-4376s. PubMed ID: 16857813
[TBL] [Abstract][Full Text] [Related]
19. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
20. Why do kinase inhibitors cause cardiotoxicity and what can be done about it?
Cheng H; Force T
Prog Cardiovasc Dis; 2010; 53(2):114-20. PubMed ID: 20728698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]